Tvardi Therapeutics Names Imran Alibhai Chief Executive Officer

Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Imran Alibhai, Ph.D. as Chief Executive Officer and a member of the Board of Directors, effective immediately.

“After a competitive national search, we are delighted to welcome Dr. Alibhai to Tvardi,” said Ron DePinho, M.D., Co-Founder and Director. “Imran’s depth and breadth of leadership experience as an executive, investor and entrepreneur will accelerate the development of our lead products through proof-of-concept trials in oncology as well as progress our programs in inflammation and fibrosis.”

Prior to joining Tvardi, Dr. Alibhai was an SVP and Managing Director at DNAtrix, a clinical-stage biopharmaceutical company developing oncolytic viruses for cancer. During his tenure, DNAtrix raised multiple rounds of financing, entered into and enrolled a Phase 2 immuno-oncology collaboration with Merck, and licensed and moved into the clinic a next-generation armed virus. Previously, Dr. Alibhai was an investment banker in PJ Solomon’s Healthcare Advisory Group, focused on M&A transactions across the life science market. Formerly, he held investing roles at Alexandria Venture Investments, MPM Capital, and the Accelerator Corp.

“I am honored that Tvardi’s board has entrusted me to lead the company,” said Dr. Alibhai. “Our lead compound, TTI-101, has already demonstrated excellent safety with early signs of activity. This activity, coupled with the pre-eminent drug developers and scholars comprising Tvardi’s founders and board, is a fantastic platform to build an innovative, successful company in Houston.”

Keith Flaherty, M.D., a member of Tvardi’s Scientific Advisory Board, Professor of Medicine at Harvard Medical School, and advisor to numerous successful companies including Plexxikon, Loxo, and Viralytics added, “I believe STAT3 is a top-five target for cancer and immunotherapy as well as for a number of other indications. Imran has a unique blend of expertise that makes him well suited to build a clinical enterprise to develop this important target.”

Source: Business Wire

Scroll to Top

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.